Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11724522 | 0.83 | TSHR (0.55) | TSHRALDH1A1KCNN4CYP1A2MAPT | |
| SCHEMBL21189687 | 0.76 | TSHR (0.42) | TSHRALDH1A1KCNN4CYP1A2MAPT | |
| SCHEMBL6001675 | 0.75 | TSHR (0.39) | TSHRKCNN4MAPTHDAC8MAPK1 | |
| SCHEMBL6337202 | 0.74 | KCNN4 (0.59) | TSHRALDH1A1KCNN4CYP1A2MAPT | |
| SCHEMBL151981 | 0.74 | TSHR (0.65) | TSHRALDH1A1KCNN4CYP1A2MAPK1 | |
| SCHEMBL10892336 | 0.74 | TSHR (0.41) | TSHRALDH1A1KCNN4CYP1A2CRHBP | |
| SCHEMBL27875145 | 0.73 | TSHR (0.38) | TSHRKCNN4MAPTHDAC8MAPK1 | |
| SCHEMBL27858532 | 0.73 | TSHR (0.38) | TSHRKCNN4MAPTHDAC8MAPK1 | |
| SCHEMBL11865406 | 0.73 | TSHR (0.44) | TSHRALDH1A1KCNN4CYP1A2MAPK1 | |
| SCHEMBL11861229 | 0.73 | KCNN4 (0.48) | TSHRALDH1A1KCNN4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1431302-B1 | PROCESS FOR SYNTHESIS OF ORGANOMETALLIC COMPOUNDS | SEKISUI CHEMICAL CO LTD (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-7361776-B2 | Zero-valent transition metal complex and method for producing an organometallic compound using the same as a starting material | SEKISUI CHEMICAL CO., LTD. (JP) | 2008-04-22 | — | — | US | disclosed |
| US-7098355-B2 | Process for synthesis of organometallic compounds | SEKISUI CHEMICAL CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20060149088-A1 | Zero-valence transition metal complex and method of synthesizing organometallic compound from the same as starting material | SEKISUI CHEMICAL CO., LTD. (JP) | 2006-07-06 | — | — | US | disclosed |
| US-20060030723-A1 | Process for synthesis of organometallic compounds | SEKISUI CHEMICAL CO., LTD. (JP) | 2006-02-09 | — | — | US | disclosed |
| EP-1431302-A1 | PROCESS FOR SYNTHESIS OF ORGANOMETALLIC COMPOUNDS | SEKISUI CHEMICAL CO., LTD. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030723-A1 | Process for synthesis of organometallic compounds | CYP4F12, CYP4F2, CYP4F11 | TSHR 3234/4885ALDH1A1 3063/4885KCNN4 2873/4885 |
| US-20060149088-A1 | Zero-valence transition metal complex and method of synthesizing organometallic compound from the same as starting material | OSTC, PORCN, SQLE | TSHR 4126/4885ALDH1A1 3035/4885KCNN4 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.